Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A3 | P48764 | 14/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13449819 | 0.96 | SLC9A3 (0.95) | SLC9A3 | |
| SCHEMBL13449817 | 0.96 | SLC9A3 (0.95) | SLC9A3 | |
| SCHEMBL2564764 | 0.93 | SLC9A3 (1.00) | SLC9A3 | |
| SCHEMBL13276401 | 0.93 | SLC9A3 (1.00) | SLC9A3 | |
| SCHEMBL2566171 | 0.93 | SLC9A3 (1.00) | SLC9A3 | |
| SCHEMBL2566163 | 0.93 | SLC9A3 (1.00) | SLC9A3 | |
| SCHEMBL2564757 | 0.93 | SLC9A3 (1.00) | SLC9A3 | |
| SCHEMBL13276402 | 0.93 | SLC9A3 (1.00) | SLC9A3 | |
| SCHEMBL22371492 | 0.93 | SLC9A3 (0.87) | SLC9A3 | |
| SCHEMBL16473627 | 0.93 | SLC9A3 (0.83) | SLC9A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2384318-B1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2014169094-A2 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC (US) | 2014-10-16 | — | — | WO | disclosed |
| WO-2010078449-A2 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2010-07-08 | — | — | WO | disclosed |